Health
TCI Revolutionizes Weight Management with Breakthrough GLP-1 Innovation
TAIPEI, Sept. 11, 2024 /PRNewswire/ -- TCI Co. Ltd. ("TCI", 8436.TWO), a global leader in ODM health and cosmetic products for over 40 years, introduces its cutting-edge GLP-1 formula, a natural blend of plant extracts, probiotics, and prebiotics designed to deliver powerful weight management res...
2024-09-11 15:56
1538
Hyundai Bioscience announces XAFTY®, a groundbreaking broad-spectrum antiviral capable of treating COVID-19, mpox, and dengue
* Hyundai Bioscience presents development updates of its broad-spectrum antiviral at the "Disease Prevention and Control Summit 2024" held in Philadelphia, USA. SEOUL, South Korea, Sept. 11, 2024 /PRNewswire/ -- Dr. Heung-Jeong Woo, a vice president of Hyundai Bioscience shared insights on the...
2024-09-11 14:25
1129
TTLife Oxygen Concentrator: A VARON-Certified Dealer, Your Reliable Partner in First Aid Preparedness
LOS ANGELES, Sept. 10, 2024 /PRNewswire/ -- TTLife Oxygen Concentrator,
2024-09-11 10:50
921
GC Cell and PT Bifarma Adiluhung sign a licensing agreement for Immuncell-LC to expand access in Indonesia
YONGIN, South Korea, Sept. 10, 2024 /PRNewswire/ -- GC Cell, a leading innovator in cell therapy, has officially announced the execution of a landmark 'Technology Transfer and License Agreement' with PT Bifarma Adiluhung(Bifarma), a premier stem cell therapy company inIndonesia. This strategic pa...
2024-09-11 09:48
1394
Study Shows Ubie Symptom Checker Accuracy Rivals Physicians, Outperforms Competitors In Providing Disease Information
* Results show Ubie's differential diagnosis platform had a Top-5 hit accuracy of 63.4% and a Top-10 hit accuracy of 71.6%; median physician accuracy was 72.9% * Ubie is effective in providing relevant information based on symptoms, making it valuable in speeding diagnosis and care delivery f...
2024-09-10 21:30
994
Lunit to Present AI-Analyzed Immune Phenotype Study as Immunotherapy Response Predictor for Advanced Gastric Cancer at ESMO Congress 2024
* Lunit SCOPE IO® demonstrates potential to assess immune phenotype as an AI-powered biomarker for predicting efficacy of Nivolumab plus Chemotherapy in advanced gastric cancer, independent of PD-L1 status SEOUL, South Korea, Sept. 10, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provi...
2024-09-10 21:00
1437
Ractigen Announces Positive Clinical Data for RAG-17 in ALS-SOD1 Treatment from Investigator-Initiated Trial
NANTONG, China and SUZHOU, China, Sept. 10, 2024 /PRNewswire/ -- Ractigen Therapeutics, a clinical-stage pharmaceutical company dedicated to developing innovative therapies, today announced promising clinical data from an Investigator-Initiated Trial (IIT) of RAG-17, a small interfering RNA (siRN...
2024-09-10 20:00
1322
I-Mab Presents Positive Uliledlimab Pharmacokinetics Data at 2024 World Conference on Lung Cancer
- Pharmacokinetic/pharmacodynamic (PK/PD) modeling data from three Phase 1 studies providing dosing support for upcoming clinical trials - Exposure-Response (E-R) Analysis showed a positive correlation between uliledlimab concentration and ORR probability in mNSCLC patients - Randomized Phase 2 st...
2024-09-10 19:00
913
Updated Data from Phase II Clinical Trial of Iruplinalkib Tablets (Qixinke®) Presented at World Conference on Lung Cancer 2024
JINAN, China, Sept. 10, 2024 /PRNewswire/ -- During the World Conference on Lung Cancer (WCLC) held fromSeptember 7-10, 2024, in San Diego, California, updated findings from the Phase II clinical trial (INTELLECT study) were presented. The study assessed the efficacy and safety of Qilu Pharmaceut...
2024-09-10 18:00
973
The 2024 International (Bozhou) TCM Expo Kicked Off
BOZHOU, China, Sept. 10, 2024 /PRNewswire/ -- On the morning of September 9, the 2024 International (Bozhou) TCM Expo and the 40th National (Bozhou) TCM Trade Fair officially kicked off in Bozhou,Anhui Province. In recent years, Bozhou has been enhancing mechanisms for the inheritance, innovatio...
2024-09-10 17:55
860
Xiao-I Corporation and the National Association of the Deaf Partner to Enhance Accessible Communication for Deaf Individuals with AI Technology
SHANGHAI, Sept. 9, 2024 /PRNewswire/ -- Xiao-I Corporation (NASDAQ: AIXI) ("Xiao-I" or the "Company"), a leading artificial intelligence company, announces that it signed a strategic partnership with the National Association of the Deaf (the "NAD"), a premier American organization dedicated to im...
2024-09-09 21:45
1665
Bambusa Therapeutics Inc. Announces Successful Series Seed Funding to Advance Innovative Bispecific Antibodies for Immunology & Inflammation
BOSTON, Sept. 9, 2024 /PRNewswire/ -- Bambusa Therapeutics Inc., a biotechnology company focused on developing bispecific antibodies for the treatment of immunological and inflammatory (I&I) disorders, announced the successful closing of its Series Seed financing round, raising approximately$15 ...
2024-09-09 21:09
1090
GenAssist Ltd Announced the First DMD Patient Dosed with its Base Editing Drug
SUZHOU, China, Sept. 9, 2024 /PRNewswire/ -- On September 06, 2024, GenAssist Ltd (GenAssist), announced the first DMD patient dosed with its base editing drug, GEN6050X injection, in an investigator-initiated trial (IIT). "This is the first-in-human trial for DMD gene editing therapy. It marks t...
2024-09-09 21:00
1155
Neurophet-NTU Singapore, recognized for outstanding joint research
- Neurophet accelerates global expansion for research and partnership in AI-driven brain image analysis SEOUL, South Korea, Sept. 9, 2024 /PRNewswire/ -- Neurophet, an artificial intelligence (AI) solution company for brain disease, announced that Neurophet and NTU (Nanyang Technological Univers...
2024-09-09 21:00
1435
Lunit Joins Roche's Digital Pathology Open Environment to Advance Cancer Biomarker Testing
* Lunit's AI-powered biomarker, Lunit SCOPE PD-L1 TPS, integrates into Roche's navify® Digital Pathology platform to enhance precision medicine and improve cancer biomarker testing SEOUL, South Korea, Sept. 9, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solution...
2024-09-09 21:00
1326
MGI Launches New Nanopore Sequencing Products with Advanced CycloneSEQ Technology
SHENZHEN, China, Sept. 9, 2024 /PRNewswire/ -- MGI Tech Co., Ltd. ("MGI"), a company committed to building core tools and technologies that drive innovation in life science, today announced the global rights to commercialize and distribute the new sequencing products CycloneSEQ-WT02* and CycloneS...
2024-09-09 16:24
1167
Formosa Pharmaceuticals Makes First Shipment of APP13007 (Clobetasol Propionate Ophthalmic Suspension, 0.05%) to the United States for Commercialization
TAIPEI, Sept. 9, 2024 /PRNewswire/ -- Formosa Pharmaceuticals, Inc. (hereinafter referred to as "Formosa Pharma," 6838.TW) announced the successful first shipment tothe United States of its new ophthalmic drug, Clobetasol Propionate Ophthalmic Suspension, 0.05% (APP13007), manufactured by Bora P...
2024-09-09 15:00
1052
Senhwa Biosciences Presents Clinical Data Abstract on Pidnarulex at 2024 ESMO Congress
* The study involved end-stage oncology patients with no other suitable treatment options. * In this Phase Ib study, Pidnarulex (CX-5461) demonstrated acceptable clinical tolerability and showed preliminary signs of efficacy, even in patients who had previously failed treatment with PARP inhi...
2024-09-09 10:33
1175
Antennova to Present Latest Data of ATN-037 in a Mini Oral Presentation at ESMO Congress 2024
BOSTON, Sept. 8, 2024 /PRNewswire/ -- Antennova, a clinical-stage biotech company focused on oncology today announced thatit will present the latest data of CD73 small molecule inhibitor ATN-037 in a Mini Oral presentation at the 2024 European Society of Medical Oncology Congress (ESMO Congress 2...
2024-09-09 08:30
1068
Perioperative Ivonescimab (PD-1/VEGF) for NSCLC Demonstrated Clinically Significant Phase II Results, Presented in Oral Session at WCLC 2024
HONG KONG, Sept. 8, 2024 /PRNewswire/ -- Akeso (9926. HK) announced that its internally developed PD-1/VEGF bispecific antibody ivonescimab showed clinically significant results from a Phase II study, either as a monotherapy or in combination with chemotherapy, for the perioperative treatment of ...
2024-09-09 02:17
1400
Week's Top Stories
Most Reposted
Going Global: DCITS Embarks on International Expansion at Singapore Fintech Festival
[Picked up by 313 media titles]
2024-11-12 09:00
DKSH Healthcare and Euris Unveil CRM & MCE Platform "ConnectPlus" to Revolutionize APAC Healthcare Distribution
[Picked up by 293 media titles]
2024-11-13 09:00
Sobot Introduces its All-in-One Solution at GITEX Global 2024
[Picked up by 291 media titles]
2024-11-12 11:00
Ubiqconn Technology to Showcase Latest Marine Solutions at the 2024 International WorkBoat Show in New Orleans
[Picked up by 289 media titles]
2024-11-11 21:00
Transformation of Asia's Process Industries To Get A Boost Through Region's First Dedicated Process Technology Show
[Picked up by 279 media titles]
2024-11-12 16:00
Most Read
Ubiqconn Technology to Showcase Latest Marine Solutions at the 2024 International WorkBoat Show in New Orleans
2024-11-11 21:00
5646
DND International Eye Hospital: Pioneering SMILE Pro Surgery & Leading the Trend of Refractive Surgery Tourism in Vietnam
2024-11-08 20:11
5573
Going Global: DCITS Embarks on International Expansion at Singapore Fintech Festival
2024-11-12 09:00
5560
HOIANA RESORT & GOLF LAUNCHES PREMIUM HOIANA PICKLEBALL COURT
2024-11-08 00:18
5536
